Finance

Beta
Roʻyxatlar
Aksiyalar sektorlari
Belgilar
Belgilar
Narxi
Oʻzgartirishlar
Dinamika (%)
Trend
Avvalgi yopilish narxi
Ochish
Yuqori
Past
Hajmi
Bozor kapitali
SIXB
Materials
SIXB
Materials
SIXB
+0,99%
1 093,81
+10,77
+0,99%
—1 083,041 082,631 099,011 080,59——
SIXC
Communications
SIXC
Communications
SIXC
+1,06%
608,77
+6,39
+1,06%
—602,38602,38609,75599,75——
SIXE
Energy
SIXE
Energy
SIXE
+0,96%
1 254,81
+11,98
+0,96%
—1 242,831 229,311 258,881 220,51——
SIXI
Industrials
SIXI
Industrials
SIXI
+2,76%
1 761,11
+47,29
+2,76%
—1 713,821 715,471 763,111 715,47——
SIXM
Financials
SIXM
Financials
SIXM
+0,40%
642,58
+2,59
+0,40%
—639,99636,98644,04631,81——
SIXR
Staples
SIXR
Staples
SIXR
+1,63%
851,13
+13,67
+1,63%
—837,46840,30852,55840,30——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1,76%
217,98
+3,76
+1,76%
—214,22214,22218,25214,05——
SIXT
Technology
SIXT
Technology
SIXT
+0,23%
3 211,83
+7,45
+0,23%
—3 204,383 215,043 217,443 159,90——
SIXU
Utilities
SIXU
Utilities
SIXU
+2,55%
948,98
+23,60
+2,55%
—925,38927,91949,76927,91——
SIXV
Health care
SIXV
Health care
SIXV
+2,20%
1 474,52
+31,81
+2,20%
—1 442,711 443,011 477,901 443,01——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+1,30%
2 392,12
+30,78
+1,30%
—2 361,342 391,002 399,182 354,52——
NTLA:NASDAQ
Intellia Therapeutics Inc
13,48 US$
+8,32%
(+1,03) 1K
13,55 US$
+0,51% (+0,069)
Yopilgandan keyin
Savdolar yopilgan: 30-apr, 16:00:00 (GMT-4)  ·   USD
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
NTLA tikeri uchun statistika yaratilmoqda...
Ochish
12,62 US$
Yuqori
14,06 US$
Past
12,62 US$
Bozor kapitali
1,59 mlrd
Oʻrtacha hajm
3,15 mln
Hajmi
13,09 mln
52 haftalik eng yuqori
28,24 US$
52 haftalik eng past
6,83 US$
Aksiya boʻyicha daromad
-3,81 US$
Beta
1,99
Muomaladagi aksiyalar
118,13 mln
Xodimlar soni
377
Yangiliklar
Internetdagi manbalardan
Profil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Intellia Therapeutics Inc haqida
CEOJohn Leonard
Xodimlar soni377
Asos solingan2014
Bosh ofislarKembrij, Massachusetts, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytintelliatx.com
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad hisoboti
Daromad
Sof foyda
Barcha qiymatlar – USD
mar, 2025
iyn, 2025
sen, 2025
dek, 2025
Daromad
16,63 mln
14,24 mln
13,78 mln
23,02 mln
Sotilgan mahsulotning tannarxi
108,43 mln
80,53 mln
78,95 mln
73,63 mln
Daromad narxi
108,43 mln
80,53 mln
78,95 mln
73,63 mln
Tadqiqot va ishlanmalarga xarajatlar
-
-
-
-
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
29,01 mln
43,71 mln
46,31 mln
48,10 mln
Operatsion xarajatlar
29,01 mln
43,71 mln
46,31 mln
48,10 mln
Jami operatsion xarajatlar
137,43 mln
124,24 mln
125,26 mln
121,73 mln
Operatsion daromad
-120,81 mln
-110,00 mln
-111,48 mln
-98,71 mln
Boshqa nooperatsion daromad
-
-
-
-
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
-114,33 mln
-101,26 mln
-101,32 mln
-95,79 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
-112,20 mln
-102,59 mln
-104,76 mln
-92,23 mln
Daromad soligʻi boʻyicha xarajat
-
-
-
-
Amaldagi soliq stavkasi
-
-
-
-
Boshqa operatsion xarajatlar
-
-
-
-
Sof foyda
-114,33 mln
-101,26 mln
-101,32 mln
-95,79 mln
Sof foyda marjasi
-687,61%
-710,81%
-735,19%
-416,15%
Har bir aksiya foydasi
-1,10
-0,98
-0,92
-0,83
Foizlar va investitsiyalardan olingan daromadlar
8,60 mln
7,40 mln
6,71 mln
6,48 mln
Foizlarni toʻlash xarajatlari
-
-
-
-
Foizlarni toʻlash boʻyicha sof xarajatlar
8,60 mln
7,40 mln
6,71 mln
6,48 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
-118,31 mln
-107,52 mln
-109,06 mln
-96,33 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-
-
-
527,00 ming
AI kontentda xatolar boʻlishi mumkin. Batafsil
YordamFikr-mulohazaMaxfiylikShartlarMajburiyatlardan voz kechish

Tahlil

Vazifalarim
Hali vazifa yaratmagansiz
Vazifalaringiz shu yerda chiqadi. Vazifalarni rejalashtiring va Google Finance xizmatidan foydalaning.
Andozalar
Kuzatuv roʻyxati brifingi
Kuzatuv roʻyxatining kunlik bozor oldidan tahlili
Kelgusi tushumlar
Hafta ichida kelgusi tushum hisobotlari
Anomal volatillik va hajm
Bugun erta ogohlantirish: volatillik va hajm
AI kontentda xatolar boʻlishi mumkin. Batafsil
YordamFikr-mulohazaMaxfiylikShartlarMajburiyatlardan voz kechish